Buzzberg Cup Bracket locked
#634 Alpha Score 25.5

Uhm Min-hyung

Pharmaceutical/Bio Analyst
· tracked since Jun 2026
634
BUZZBERG Alpha Score combines three things: realized average return, confidence in the sample size, idea volume, and speaker reputation. Speakers with only a few calls are pulled closer to the platform average; speakers with many evaluated ideas keep more of their own return. Reputation only boosts: 5.0 or lower is neutral, while scores above 5 add weight. Scores are normalized to 0-100; 100 is best. Read the FAQ
Alpha Score 25.5
Calls
5
Win Rate
0.0%
Return
-9.8%
Calls 5 1 Posts tracked · 0.3/day
Calls
7d 5
30d 5
90d 5
Best Calls
No live winners yet
Worst Calls
087010.KQ long -11.0%
347850.KQ long -10.9%
196170.KQ long -10.5%
Most Mentioned
196170.KQ ×1
141080.KQ ×1
226950.KQ ×1
Recent Calls
347850.KQ long 3 days ago
087010.KQ long 3 days ago
141080.KQ long 3 days ago
Win Rate 0% Long 5 Short 0
Win Rate
7d —
30d —
90d —
Average Return -9.8% Long Return -9.8% Short Return -
Average Return
7d —
30d —
90d —
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
Opened
Entry
P&L
Thesis
Theme
Source
087010.KQ Peptron Peptron
Long
Jun 25
$187700.00
-11.0%
Lilly obesity deal finalization expected
Peptron is a preferred name as its long-acting obesity treatment partnership with Eli Lilly is expected to move toward a definitive agreement, providing a large deal catalyst.
Healthcare
YOUTUBE
141080.KQ LigaChem... LigaChem Biosciences Inc.
Long
Jun 25
$158200.00
-9.7%
ADC clinical results release ahead
LegoChem Bio is a preferred name with an upcoming official release of clinical results for its ADC asset LCB84, which could act as a near-term catalyst.
Healthcare
YOUTUBE
196170.KQ Alteogen Alteogen
Long
Jun 25
$384000.00
-10.5%
Top pick after patent win and contracts
Alteogen is the sector top pick. It won a patent nullification suit against Halozyme, removing uncertainty, and became the first Korean biotech to sign two technology transfer deals in a single quarter with GSK and Biogen, proving its platform value and dealmaking capability.
Healthcare
YOUTUBE
226950.KQ OliX Pha... OliX Pharmaceuticals, Inc.
Long
Jun 25
$144400.00
-6.8%
L'Oréal deal funds self-sufficient R&D
Olix is viewed as the second-best biotech after Alteogen. Its cosmetics commercialization with L'Oréal will generate revenue that can self-fund clinical development without additional capital raises, transforming it into a self-sustaining R&D company.
Other
YOUTUBE
347850.KQ D&D Phar... D&D Pharmatech Inc.
Long
Jun 25
$87200.00
-10.9%
MASH drug outperforms big pharma, deal likely
DND Pharmatech's MASH treatment candidate demonstrated statistical significance across all three endpoints including fibrosis improvement, where Boehringer Ingelheim previously failed. This scientific edge makes a large-scale technology transfer highly likely.
Healthcare
YOUTUBE
Showing 5 of 5 picks · sorted by mentions

Uhm Min-hyung has 5 trade ideas tracked on Buzzberg across 5 tickers since June 2026. Ranked #634 on the Buzzberg Alpha leaderboard. Most covered: 196170.KQ, 141080.KQ, 226950.KQ.